Eupraxia Pharmaceuticals Inc
TSX:EPRX
Intrinsic Value
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of EPRX.
Eupraxia Pharmaceuticals Inc's market capitalization is 143.9m CAD.
EPRX stock price is 4.04 CAD.
EPRX.
EPRX. Open DCF Valuation
EPRX. Open Relative Valuation
EPRX has upside potential of 298% compared to the average analyst price target.
Open Wall St Estimates
EPRX has negative Free Cash Flow for the last twelve months.
EPRX's short-term assets (20m CAD) exceed its short-term liabilties (19m CAD).
EPRX's long-term assets (20m CAD) exceed its long-term liabilties (18m CAD).
EPRX has negative Operating Income for the last twelve months.
EPRX has negative Net Income for the last twelve months.
EPRX's ROE (Return on Equity) has significantly decreased in the last 3 years from -43% to -374%, and is approaching profitability.
EPRX's ROE (Return on Equity) for the past 12 months is negative and is equal to -374%.
EPRX's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 957%.
EPRX has very high three-year average ROE (Return on Equity): 191%. The company is very efficient at transforming stockholders' equity into net income.
EPRX has very high three-year average ROIC (Return on Invested Capital): 1 185%. The company is very efficient at using invested capital to generate operating income.
EPRX's D/E (Debt to Equity) is very low and is equal to 0.
EPRX's Altman Z-Score is very low and is equal to -6.52.
Fundamental Analysis
Eupraxia Pharmaceuticals Inc
Balance Sheet Decomposition
Eupraxia Pharmaceuticals Inc
| Current Assets | 19.8m |
| Cash & Short-Term Investments | 19.3m |
| Receivables | 190.6k |
| Other Current Assets | 270.7k |
| Non-Current Assets | 463.2k |
| PP&E | 456.3k |
| Other Non-Current Assets | 6.9k |
| Current Liabilities | 19.4m |
| Accounts Payable | 3.9m |
| Accrued Liabilities | 18.4k |
| Other Current Liabilities | 15.5m |
| Non-Current Liabilities | -1.3m |
| Other Non-Current Liabilities | -1.3m |
Earnings Waterfall
Eupraxia Pharmaceuticals Inc
|
Revenue
|
0
CAD
|
|
Operating Expenses
|
-27.4m
CAD
|
|
Operating Income
|
-27.4m
CAD
|
|
Other Expenses
|
-777.6k
CAD
|
|
Net Income
|
-28.2m
CAD
|
Free Cash Flow Analysis
Eupraxia Pharmaceuticals Inc
What is Free Cash Flow?
EPRX Profitability Score
Profitability Due Diligence
Eupraxia Pharmaceuticals Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Eupraxia Pharmaceuticals Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
EPRX Solvency Score
Solvency Due Diligence
Eupraxia Pharmaceuticals Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Eupraxia Pharmaceuticals Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPRX Price Targets Summary
Eupraxia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
EPRX
is 16.07 CAD
with a low forecast of 15.15 CAD and a high forecast of 17.33 CAD.
Shareholder Return
EPRX Price
Eupraxia Pharmaceuticals Inc
| Average Annual Return | -2.92% |
| Standard Deviation of Annual Returns | 89.34% |
| Max Drawdown | -87% |
| Market Capitalization | 143.9m CAD |
| Shares Outstanding | 35 622 600 |
| Percentage of Shares Shorted | 0.06% |
Company Profile
Eupraxia Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
You don't have any saved screeners yet
